This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Banumathy G , Cairns P
Signaling pathways in renal cell carcinoma
Cancer Biology & Therapy. 2010 Oct;10(7) :658-664
PMID: ISI:000282447300002 PMCID: PMC3093809
AbstractRenal cell carcinoma (RCC), the most lethal type of genitourinary cancer, is generally resistant to chemotherapy and radiation therapy. Surgical excision of the tumor at a localized stage remains the mainstay for curative therapy. A number of drugs developed in recent years have shown limited to significant efficacy in treating RCC. These drugs act by blocking critical signaling pathways associated with RCC tumor growth and survival and angiogenesis. Beyond well-validated signaling targets such as VHL, VEGFR and mTOR, additional pathways including HGF/c-MET and Wnt/beta-catenin have emerged as important to RCC pathogenesis. Mutations in one or more components of these signaling networks may affect tumor response to therapy. This review summarizes the state of knowledge about signaling pathways in RCC and discusses the known genetic and epigenetic alterations that underlie dysregulation of these pathways.
NotesBanumathy, Gowrishankar Cairns, Paul National Cancer Institute [P30 CA006927]; Fox Chase Cancer Center The authors would like to thank and acknowledge Erica Golemis and Gary R. Hudes at FCCC for their reading and input to this review. This publication was supported in part by grant number P30 CA006927 from the National Cancer Institute. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Additional funds were provided by Fox Chase Cancer Center via institutional support of the Kidney Keystone Program. 104 Landes bioscience; 1002 west avenue, 2nd floor, austin, tx 78701 usa 657vs